Last reviewed · How we verify
Estrogens and Progestogens
At a glance
| Generic name | Estrogens and Progestogens |
|---|---|
| Also known as | Hormone replacement therapy |
| Sponsor | VU University of Amsterdam |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer
- Oral Contraceptive (OC) Estrogen Dose and Breast Proliferation (NA)
- MHT and Liver Function in Postmenopausal Women (NA)
- Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis (PHASE2, PHASE3)
- Role of Estrogen on Skeletal Outcomes in FHA (PHASE2)
- Frozen Shoulder and Hormone Replacement Therapy (PHASE4)
- Ventricular Repolarization in Patients With Premature Ovarian Insufficiency (QTIOP) (NA)
- Evaluation of Anterior Tibial Knee Translation in Healthy Women With and Without Hormone Therapy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Estrogens and Progestogens CI brief — competitive landscape report
- Estrogens and Progestogens updates RSS · CI watch RSS
- VU University of Amsterdam portfolio CI